WebNovaBiotics Ltd is a leading clinical-stage biotechnology company focused on leveraging its novel immunology platforms to design and develop first-in-class therapies to address difficult-to-treat, medically unmet diseases. The Company’s advanced portfolio of … NovaBiotics’ experienced board and management team remain focused on … All of NovaBiotics IP has been generated in-house and is wholly owned by the … NovaBiotics Inc One Boston Place, Suite 2600, Boston MA, 02108. Tel:+1 866 259 … WebFeb 5, 2016 · Aberdeen firm NovaBiotics won the award for investment of the year at the Scottish Enterprise (SE) Life Sciences Awards in Edinburgh last night. ... A two-lane Bridge of Don? 7 plans for Aberdeen ...
NOVABIOTICS LIMITED Company Profile - Dun & Bradstreet
WebJan 4, 2024 · The innovative business has just completed the move into its new 6,000sq ft laboratory and office facility at Bridge of Don Industrial Estate. Relocation is the first step in a planned... WebAddress: Silverburn Crescent Bridge of Don Industrial Estate ABERDEEN, AB23 8EW United Kingdom See other locations Phone: Website: www.novabiotics.co.uk Employees (this site): Estimated Revenue: Actual Fiscal Year End: Year Started: Incorporated: ESG ranking: ESG industry average: What is D&B's ESG Ranking? Is this your business? cute girl cat names for gray cats
NovaBiotics Ltd, Aberdeen - Pharmaceutical company in A
WebView NovaBiotics (www.novabiotics.co.uk) location in Aberdeen City, United Kingdom , revenue, industry and description. Find related and similar companies as well as employees by title and much more. ... Silverburn Don Cres, Aberdeen, Aberdeen City, AB23 8EW, United Kingdom. Phone Number +44 1224711377. Website. www.novabiotics.co.uk. Revenue ... WebDec 29, 2024 · NovaBiotics are delighted to announce that our CARE CF 1 phase 2b clinical trial data for oral Lynovex in infectious pulmonary exacerbations of cystic fibrosis is published today in PLOS ONE. Our findings further support the potential of Lynovex® as game-changer in CF therapy. WebNovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals. cute girl board shorts